Description

Remdesivir is an RNA polymerase inhibitor for treating COVID-19 in adults and pediatric patients (12 years and older, weighing 40 kg or more) with positive SARS-CoV-2 test results.
Treatment is for hospitalized patients or those not hospitalized but at risk of progression to severe COVID-19.

Dosage and Side Effects

Pre-treatment renal and hepatic testing for all patients before and during therapy.
Recommendations for dosage based on patient condition and hospitalization status.
Administered via intravenous infusion over 30 to 120 minutes.

Common adverse reactions observed include nausea, increased ALT, and increased AST.

Alerts about hypersensitivity reactions during or post-administration, with suggestions for slower infusion rates and close monitoring.
Highlighted risk of liver enzyme elevations and reduced antiviral activity when coadministered with certain medication.

What’s Remdesivir for?

Remdesivir Injection treats COVID-19 in adults and pediatric patients at risk of severe symptoms or hospitalization.

How is it given?

Remdesivir is infused intravenously over 30-120 minutes, typically with a loading dose followed by daily maintenance doses.

Common side effects?

Nausea, increased liver enzymes (ALT, AST), and occasional hypersensitivity reactions during or after infusion.

Any medication interactions?

Avoid using Remdesivir with chloroquine or hydroxychloroquine. Patients with poor kidney function should also avoid it.

Safety during pregnancy?

Remdesivir can harm unborn babies, so strict precautions to avoid pregnancy during treatment are essential.